

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock code: 950)

VOLUNTARY ANNOUNCEMENT ESTABLISHMENT OF THE GROUP COMMERCIAL OPERATIONS CENTRE

This announcement is made by the board of directors (the “**Board**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board of the Company is pleased to announce that the Group Commercial Operations Centre (“**GCOC**”) has been officially established on 22 October 2020. The GCOC is a dedicated unit to manage all aspects of the Group’s commercial operations in China, such as to enhance the efficiency and effectiveness thereof, to respond to rapidly changing pharmaceutical market environment and business needs, to unleash the full potential of the launched products, to enhance the readiness for new product launch, and with a view to achieve steady and sustainable sales growth.

Mr. Sun Guorui (“**Mr. Sun**”) joined the Group in September 2020 and currently has been appointed as the General Manager of GCOC. He holds a Master of Business Administration degree from Peking University and a bachelor’s degree in Engineering from Sichuan University. Prior to joining the Group, he worked for several multinational pharmaceutical and healthcare companies in China, including Bayer Healthcare Company Limited, Beijing Novartis Pharma Co. Limited and Daiichi Pharmaceutical Co. Limited. He has more than 20 years of business and senior management experience in pharmaceutical industry and is experienced in leading sizable teams to perform sales and marketing activities across China.

Mr. Zhang Zeyun (“**Mr. Zhang**”) has been promoted to Deputy General Manager of GCOC. He joined the Group in October 2018 and is responsible for the business management of the Group’s commercial operation, sales of oncology products and retail sales business in China. He graduated from Guangzhou University of Chinese Medicine with a bachelor’s degree in Chinese Medicine. Before joining the Group, he worked for several multinational pharmaceutical and healthcare companies in China for over 15 years and was responsible for sales and market access management. In March 2019, he has been appointed as Commercial Operations Director of the Group and Executive Deputy General Manager of Guangzhou Zhaoke Lian Fa Pharmaceutical Limited.

The Board would like to take this opportunity to express its warmest welcome to Mr. Sun on his new appointment and congratulate Mr. Zhang on his promotion.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 23 October 2020

** For identification purpose only*

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive directors of the Company, Mr. Simon Miles Ball is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.